Cargando…

Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study

AIM: The goal of this study was to determine if long-term testosterone (T) therapy in men with hypogonadism, henceforth referred to as testosterone deficiency (TD), ameliorates or improves metabolic syndrome (MetS) components. METHODS: We performed a cumulative registry study of 255 men, aged betwee...

Descripción completa

Detalles Bibliográficos
Autores principales:	Traish, A M, Haider, A, Doros, G, Saad, F
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BlackWell Publishing Ltd 2014
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4282282/ https://www.ncbi.nlm.nih.gov/pubmed/24127736 http://dx.doi.org/10.1111/ijcp.12319

Ejemplares similares

SUN-083 Hypertension and Hemodynamic Parameters in Men with Hypogonadism Improve Under Long-Term Treatment with Testosterone Undecanoate Injections (TU) Compared to Untreated Hypogonadal Control Patients
por: Saad, Farid, et al.
Publicado: (2019)

SUN-226 Improvements In Quality Of Life In Men With Hypogonadism Under Long-term Testosterone Therapy (TTh) With Testosterone Undecanoate Injections (TU): Experience From 6,500 Patient-years Ina Registry Study Ina Urological Setting
por: Haider, Karim, et al.
Publicado: (2019)

SUN-055 Reduction of Mortality and Major Adverse Cardiovascular Events (MACE) in Men with Hypogonadism Treated with Long-Term Testosterone Therapy (TTh) with Testosterone Undecanoate Injections (TU): 10-Year Data from a Registry Study in a Urological Setting
por: Saad, Farid, et al.
Publicado: (2019)

OR21-2 Lipid Profiles Improve in Men With Hypogonadism and Pre-existing Cardiovascular Disease Under Long-term Testosterone Therapy (TTh) With Testosterone Undecanoate Injections (TU): 10-year Data From a Controlled Registry Study in a Urological Setting
por: Haider, Ahmad, et al.
Publicado: (2019)

Long-Term Testosterone Therapy Improves Cardiometabolic Function and Reduces Risk of Cardiovascular Disease in Men with Hypogonadism: A Real-Life Observational Registry Study Setting Comparing Treated and Untreated (Control) Groups
por: Traish, Abdulmaged M., et al.
Publicado: (2017)

MON-091 Profound and Sustained Weight Loss in Men With Hypogonadism and Obesity Receiving Long-Term Testosterone Therapy (TTh) with Testosterone Undecanoate Injections (TU): 10-Year Data from a Registry Study in a Urological Setting
por: Haider, Karim, et al.
Publicado: (2019)

SAT-533 Men with Hypogonadism and Osteoporosis Benefit from Long-Term Testosterone Therapy (TTh) with Testosterone Undecanoate Injections (TU) Regardless of Co-Medication with Bisphosphonates: 10-Year Data from a Controlled Registry Study in a Urological Setting
por: Haider, Ahmad, et al.
Publicado: (2019)

Effects of long-term treatment with testosterone on weight and waist size in 411 hypogonadal men with obesity classes I-III: observational data from two registry studies
por: Saad, F, et al.
Publicado: (2016)

Effects of Long-Term Testosterone Therapy on Patients with “Diabesity”: Results of Observational Studies of Pooled Analyses in Obese Hypogonadal Men with Type 2 Diabetes
por: Haider, Ahmad, et al.
Publicado: (2014)

Remission of type 2 diabetes following long‐term treatment with injectable testosterone undecanoate in patients with hypogonadism and type 2 diabetes: 11‐year data from a real‐world registry study
por: Haider, Karim Sultan, et al.
Publicado: (2020)

SUN-222 Testosterone Treatment in Men with Classical vs. Functional Hypogonadism: A 9-Year Registry
por: Zitzmann, Michael, et al.
Publicado: (2019)

Differential effects of 11 years of long-term injectable testosterone undecanoate therapy on anthropometric and metabolic parameters in hypogonadal men with normal weight, overweight and obesity in comparison with untreated controls: real-world data from a controlled registry study
por: Saad, F., et al.
Publicado: (2020)

Men with testosterone deficiency and a history of cardiovascular diseases benefit from long-term testosterone therapy: observational, real-life data from a registry study
por: Haider, Ahmad, et al.
Publicado: (2016)

Long-term Opioids Linked to Hypogonadism and the Role of Testosterone Supplementation Therapy
por: Marudhai, Suganya, et al.
Publicado: (2020)

Long-term testosterone replacement therapy reduces fatigue in men with hypogonadism
por: de Almeida Ferreira, Maurício, et al.
Publicado: (2022)

Remission of type 2 diabetes in a hypogonadal man under long-term testosterone therapy
por: Haider, Ahmad, et al.
Publicado: (2017)

Progressive Improvement of T-Scores in Men with Osteoporosis and Subnormal Serum Testosterone Levels upon Treatment with Testosterone over Six Years
por: Haider, Ahmad, et al.
Publicado: (2014)

Elderly men over 65 years of age with late-onset hypogonadism benefit as much from testosterone treatment as do younger men
por: Saad, Farid, et al.
Publicado: (2015)

Testosterone therapy in hypogonadal men results in sustained and clinically meaningful weight loss
por: Yassin, AA, et al.
Publicado: (2013)

The impact of long-term Testosterone Therapy (TTh) in renal function (RF) among hypogonadal men: An observational cohort study
por: Alwani, Mustafa, et al.
Publicado: (2021)

PMON260 Cost-Effectiveness of Testosterone Treatment for Men with Hypogonadism
por: Jayasena, Channa, et al.
Publicado: (2022)

Remission of type 2 diabetes and pleiotropic effects of long-term testosterone treatment for “late-onset” hypogonadism: A case report
por: Haider, Ahmad, et al.
Publicado: (2019)

Psychosexual Development in Men with Congenital Hypogonadotropic Hypogonadism on Long-Term Treatment: A Mixed Methods Study
por: Dwyer, Andrew A, et al.
Publicado: (2015)

Hypogonadal men with moderate-to-severe lower urinary tract symptoms have a more severe cardiometabolic risk profile and benefit more from testosterone therapy than men with mild lower urinary tract symptoms
por: Saad, Farid, et al.
Publicado: (2018)

Voiding function improves under long-term testosterone treatment (TTh) in hypogonadal men, independent of prostate size
por: Yassin, Aksam, et al.
Publicado: (2023)

ODP412 High Frequency of Erythrocytosis in Hypogonadal Men on Testosterone Replacement Therapy
por: Pérez-Luis, Jesús, et al.
Publicado: (2022)

OR25-06 The Effect of Testosterone Replacement Therapy on NAFLD in Elderly Hypogonadal Men
por: Seung Lee, Hae, et al.
Publicado: (2023)

Early Treatment of Hypothalamic Hypogonadism With LH-RH Analog Improved the Long-Term Prognosis of Hypogonadism of Adult-Onset Craniopharyngioma
por: Iwabuchi, Masayasu
Publicado: (2021)

Cardiovascular Disease, Hypogonadism and Erectile Dysfunction: Early Detection, Prevention and the Positive Effects of Long-Term Testosterone Treatment: Prospective Observational, Real-Life Data
por: Alwani, Mustafa, et al.
Publicado: (2021)

Impact of Short-Acting vs Long-Acting Testosterone Therapy on Intratesticular Testosterone Using Data From Two Open-Label Randomized Clinical Trials of Testosterone Pellets, Injections, and Intranasal Gel in Hypogonadal Men
por: Kresch, Eliyahu, et al.
Publicado: (2021)

The complications of male hypogonadism: is it just a matter of low testosterone?
por: Munari, Elisabetta Veronica, et al.
Publicado: (2023)

Hypogonadism in adolescent girls: treatment and long-term effects
por: Voutsadaki, Kleanthi, et al.
Publicado: (2022)

Osteocalcin Levels in Male Idiopathic Hypogonadotropic Hypogonadism: Relationship With the Testosterone Secretion and Metabolic Profiles
por: Yang, Yu-Ying, et al.
Publicado: (2019)

SUN-LB114 Remission of Type 2 Diabetes (DMT2) in Hypogonadal Men Under Long-Term Testosterone Therapy
por: Mskhalaya, George, et al.
Publicado: (2020)

UGT2B17 Genotype and the Pharmacokinetic Serum Profile of Testosterone during Substitution Therapy with Testosterone Undecanoate. A Retrospective Experience from 207 Men with Hypogonadism
por: Bang, Anne Kirstine, et al.
Publicado: (2013)

Testosterone therapy in men with testosterone deficiency: Are we beyond the point of no return?
por: Traish, Abdulmaged
Publicado: (2016)

PMON258 Patient-Reported Outcomes for men with Hypogonadism and the Impact of Low Testosterone Levels: a review of measures
por: Jayasena, Channa N, et al.
Publicado: (2022)

SAT-LB6 First Human Trial of an Oral Native Testosterone Shows Physiological Levels of Testosterone and Dht in Both Fasted and Fed State in Hypogonadal Men
por: Newell-Price, John D C, et al.
Publicado: (2020)

MON-246 Long-Term Impact of Recombinant Follicle Stimulating Hormone Treatment in Five Infants with Hypogonadotropic Hypogonadism
por: Kohva, Ella, et al.
Publicado: (2019)

SAT-038 Ambulatory Blood Pressure Increases in Hypogonadal Men Who Develop Increases in Hematocrit on Oral Testosterone Undecanoate
por: Dobs, Adrian Sandra, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_1fcvrdv3f50iojp71ulpus8pdm